/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
and Strategy Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system ( CNS ) diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our clinical trials.
$2.42
+$0.01 (+0.41%)
EOD Sep 18, 2026
ROIC dropped from -31.87% to -37.76%, capital efficiency is deteriorating. Negative free cash flow of -$39M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$13M
▼ -7.8% YoY
Op. Margin
—
ROIC
-12.05%
▼ -5.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$29M
▼ -26.7% YoY
Op. Cash Flow (TTM)
-$29M
▼ -26.7% YoY
Net Debt
-$118M
Net Cash Position
Cash & Equiv.
$118M
Continue Research
SourceComputed from the 10-Q filed 28 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 29 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Sep. Sector medians are approximate S&P 500 benchmarks and update periodically.